Essential Thrombocythemia

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

By

A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

By

A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

By

Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

By

Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs